2-Tert-butylpyrrolo[1,2-a]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 2-Tert-butylpyrrolo[1,2-a]pyrimidine
• 英文别名: 2-tert-butylpyrrolo[1,2-a]pyrimidine
• 化学式: C₁₁H₁₄N₂
• 分子量: 174.24
• InChiKey: GKCQPQOPJGZLGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS
  申请人：Su Wei-Guo

  公开号：US20140121200A1

  公开（公告）日：2014-05-01

  Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R 1 , R 2 , R 3 , R 4 and m are as defined in the specification.

  提供了式（1）的吡啶吡嗪化合物，以及其药物组合物和使用方法，其中R1、R2、R3、R4和m如规范中所定义。
• PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF
  申请人：HUTCHISON MEDIPHARMA LIMITED

  公开号：US20160228443A1

  公开（公告）日：2016-08-11

  The present disclosure provides pyrrolopyrimidine compounds and methods of use therefor. For example, the disclosure provides certain pyrrolopyrimidine compounds capable of inhibiting JAK kinases. The disclosure further provides the pharmaceutical compositions containing these pyrrolopyrimidine compounds, and use of these pyrrolopyrimidine compounds in the treatment of disorders or diseases, such as inflammatory diseases and cancer.

  本文提供了吡咯并嘧啶化合物及其使用方法。例如，本文提供了某些能够抑制JAK激酶的吡咯并嘧啶化合物。本文还提供了含有这些吡咯并嘧啶化合物的制药组合物，并将这些吡咯并嘧啶化合物用于治疗炎症性疾病和癌症等疾病或疾病的方法。
• Substituted heteroaryl compounds and methods of use
  申请人：Sunshine Lake Pharma Co., Ltd.

  公开号：US10683297B2

  公开（公告）日：2020-06-16

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

  本发明提供了新型杂芳基化合物、药物可接受盐及其制剂。它们可用于预防、控制、治疗或减轻蛋白激酶介导的疾病的严重程度。本发明还提供了包含此类化合物的药学上可接受的组合物，以及使用该组合物治疗蛋白激酶介导的疾病的方法。
• 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS
  申请人：Shapiro Gideon

  公开号：US20180170935A1

  公开（公告）日：2018-06-21

  Disclosed are chemical entities of Formula (I), wherein R 1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
• SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE
  申请人：Xi Ning

  公开号：US20190152977A1

  公开（公告）日：2019-05-23

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.